Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Oral Doses of CJ-12420 (Tegoprazan), A Novel Potassium-Competitive Acid Blocker (P-CAB) in Healthy Male Subjects
The plasma concentrations of CJ-12420 and its metabolite, M1, were determined using a validated liquid chromatography-mass spectrometry method. The pharmacodynamic analysis of the SAD and MAD study showed rapid onset and dose-dependent gastric acid suppression.
Gespeichert in:
| Veröffentlicht in: | Clinical therapeutics 2017-08, Vol.39 (8), p.e97-e98 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e98 |
|---|---|
| container_issue | 8 |
| container_start_page | e97 |
| container_title | Clinical therapeutics |
| container_volume | 39 |
| creator | Han, S Choi, H. Youn Kim, Y. Han Nam, J. Yeon Song, G. Seog Lim, H.-S Bae, K.-S |
| description | The plasma concentrations of CJ-12420 and its metabolite, M1, were determined using a validated liquid chromatography-mass spectrometry method. The pharmacodynamic analysis of the SAD and MAD study showed rapid onset and dose-dependent gastric acid suppression. |
| doi_str_mv | 10.1016/j.clinthera.2017.05.306 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1912661634</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0149291817306045</els_id><sourcerecordid>1912661634</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2926-ee51eaec06a12b9dc2b0139e494d7838688e12f9a464825e92cd0765c6e65e993</originalsourceid><addsrcrecordid>eNqNUt1u0zAUjhBIlMEzYImbTWqC7SROfIPUhcFAG6vUInFnuc7p6taJO9utFF6SV8JZ0ZC44sbWOfp-ztF3kuQtwRnBhL3fZsroPmzAyYxiUmW4zHLMniUTUlc8JaT48TyZYFLwlHJSv0xeeb_FGOe8pJPk10KuIQxTtLQmKqy00WM130jXSWV3uoeglZ8i2bdP3XboZRe7yK7RlVfSyKD7e7SIj4FH5O3BBL2PxZ2TBn20Hh7BzdeU0IJidL6Ee7t38qfsL6Zohr7ZIxg0t0F6rw9d2thuH42DPgKaKd2iS2PVDhw6n6fN7PIC6R5dgzRhM6BbGX0Wh9UWVPCvkxdraTy8-fOfJd8_XS2b6_Tm7vOXZnaTKsopSwFKAhIUZpLQFW8VXWGScyh40VZ1XrO6BkLXXBasqGkJnKoWV6xUDFiseH6WvDvp7p19OIAPYmsPro-WgnBCGSMsLyKqOqGUs947WIu90510gyBYjOmJrXhKT4zpCVyKmF5kzk5MiEscNTjhlYZeQatd3FO0Vv-Hxod_NEacjnntYAD_d2DhqcBiMd7IeCKkimxclPlvu9O8sg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1912661634</pqid></control><display><type>article</type><title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Oral Doses of CJ-12420 (Tegoprazan), A Novel Potassium-Competitive Acid Blocker (P-CAB) in Healthy Male Subjects</title><source>Elsevier ScienceDirect Journals Complete</source><source>ProQuest Central UK/Ireland</source><creator>Han, S ; Choi, H. Youn ; Kim, Y. Han ; Nam, J. Yeon ; Song, G. Seog ; Lim, H.-S ; Bae, K.-S</creator><creatorcontrib>Han, S ; Choi, H. Youn ; Kim, Y. Han ; Nam, J. Yeon ; Song, G. Seog ; Lim, H.-S ; Bae, K.-S</creatorcontrib><description>The plasma concentrations of CJ-12420 and its metabolite, M1, were determined using a validated liquid chromatography-mass spectrometry method. The pharmacodynamic analysis of the SAD and MAD study showed rapid onset and dose-dependent gastric acid suppression.</description><identifier>ISSN: 0149-2918</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2017.05.306</identifier><language>eng</language><publisher>Bridgewater: Elsevier Inc</publisher><subject>Acids ; Gastroesophageal reflux ; Internal Medicine ; Liquid chromatography ; Mass spectrometry ; Mass spectroscopy ; Medical Education ; Pharmacodynamics ; Pharmacokinetics ; Pharmacology ; Potassium</subject><ispartof>Clinical therapeutics, 2017-08, Vol.39 (8), p.e97-e98</ispartof><rights>2017</rights><rights>Copyright Elsevier Limited Aug 2017</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2926-ee51eaec06a12b9dc2b0139e494d7838688e12f9a464825e92cd0765c6e65e993</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1912661634?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64389,72469</link.rule.ids></links><search><creatorcontrib>Han, S</creatorcontrib><creatorcontrib>Choi, H. Youn</creatorcontrib><creatorcontrib>Kim, Y. Han</creatorcontrib><creatorcontrib>Nam, J. Yeon</creatorcontrib><creatorcontrib>Song, G. Seog</creatorcontrib><creatorcontrib>Lim, H.-S</creatorcontrib><creatorcontrib>Bae, K.-S</creatorcontrib><title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Oral Doses of CJ-12420 (Tegoprazan), A Novel Potassium-Competitive Acid Blocker (P-CAB) in Healthy Male Subjects</title><title>Clinical therapeutics</title><description>The plasma concentrations of CJ-12420 and its metabolite, M1, were determined using a validated liquid chromatography-mass spectrometry method. The pharmacodynamic analysis of the SAD and MAD study showed rapid onset and dose-dependent gastric acid suppression.</description><subject>Acids</subject><subject>Gastroesophageal reflux</subject><subject>Internal Medicine</subject><subject>Liquid chromatography</subject><subject>Mass spectrometry</subject><subject>Mass spectroscopy</subject><subject>Medical Education</subject><subject>Pharmacodynamics</subject><subject>Pharmacokinetics</subject><subject>Pharmacology</subject><subject>Potassium</subject><issn>0149-2918</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNUt1u0zAUjhBIlMEzYImbTWqC7SROfIPUhcFAG6vUInFnuc7p6taJO9utFF6SV8JZ0ZC44sbWOfp-ztF3kuQtwRnBhL3fZsroPmzAyYxiUmW4zHLMniUTUlc8JaT48TyZYFLwlHJSv0xeeb_FGOe8pJPk10KuIQxTtLQmKqy00WM130jXSWV3uoeglZ8i2bdP3XboZRe7yK7RlVfSyKD7e7SIj4FH5O3BBL2PxZ2TBn20Hh7BzdeU0IJidL6Ee7t38qfsL6Zohr7ZIxg0t0F6rw9d2thuH42DPgKaKd2iS2PVDhw6n6fN7PIC6R5dgzRhM6BbGX0Wh9UWVPCvkxdraTy8-fOfJd8_XS2b6_Tm7vOXZnaTKsopSwFKAhIUZpLQFW8VXWGScyh40VZ1XrO6BkLXXBasqGkJnKoWV6xUDFiseH6WvDvp7p19OIAPYmsPro-WgnBCGSMsLyKqOqGUs947WIu90510gyBYjOmJrXhKT4zpCVyKmF5kzk5MiEscNTjhlYZeQatd3FO0Vv-Hxod_NEacjnntYAD_d2DhqcBiMd7IeCKkimxclPlvu9O8sg</recordid><startdate>20170801</startdate><enddate>20170801</enddate><creator>Han, S</creator><creator>Choi, H. Youn</creator><creator>Kim, Y. Han</creator><creator>Nam, J. Yeon</creator><creator>Song, G. Seog</creator><creator>Lim, H.-S</creator><creator>Bae, K.-S</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20170801</creationdate><title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Oral Doses of CJ-12420 (Tegoprazan), A Novel Potassium-Competitive Acid Blocker (P-CAB) in Healthy Male Subjects</title><author>Han, S ; Choi, H. Youn ; Kim, Y. Han ; Nam, J. Yeon ; Song, G. Seog ; Lim, H.-S ; Bae, K.-S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2926-ee51eaec06a12b9dc2b0139e494d7838688e12f9a464825e92cd0765c6e65e993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Acids</topic><topic>Gastroesophageal reflux</topic><topic>Internal Medicine</topic><topic>Liquid chromatography</topic><topic>Mass spectrometry</topic><topic>Mass spectroscopy</topic><topic>Medical Education</topic><topic>Pharmacodynamics</topic><topic>Pharmacokinetics</topic><topic>Pharmacology</topic><topic>Potassium</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Han, S</creatorcontrib><creatorcontrib>Choi, H. Youn</creatorcontrib><creatorcontrib>Kim, Y. Han</creatorcontrib><creatorcontrib>Nam, J. Yeon</creatorcontrib><creatorcontrib>Song, G. Seog</creatorcontrib><creatorcontrib>Lim, H.-S</creatorcontrib><creatorcontrib>Bae, K.-S</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Han, S</au><au>Choi, H. Youn</au><au>Kim, Y. Han</au><au>Nam, J. Yeon</au><au>Song, G. Seog</au><au>Lim, H.-S</au><au>Bae, K.-S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Oral Doses of CJ-12420 (Tegoprazan), A Novel Potassium-Competitive Acid Blocker (P-CAB) in Healthy Male Subjects</atitle><jtitle>Clinical therapeutics</jtitle><date>2017-08-01</date><risdate>2017</risdate><volume>39</volume><issue>8</issue><spage>e97</spage><epage>e98</epage><pages>e97-e98</pages><issn>0149-2918</issn><eissn>1879-114X</eissn><abstract>The plasma concentrations of CJ-12420 and its metabolite, M1, were determined using a validated liquid chromatography-mass spectrometry method. The pharmacodynamic analysis of the SAD and MAD study showed rapid onset and dose-dependent gastric acid suppression.</abstract><cop>Bridgewater</cop><pub>Elsevier Inc</pub><doi>10.1016/j.clinthera.2017.05.306</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0149-2918 |
| ispartof | Clinical therapeutics, 2017-08, Vol.39 (8), p.e97-e98 |
| issn | 0149-2918 1879-114X |
| language | eng |
| recordid | cdi_proquest_journals_1912661634 |
| source | Elsevier ScienceDirect Journals Complete; ProQuest Central UK/Ireland |
| subjects | Acids Gastroesophageal reflux Internal Medicine Liquid chromatography Mass spectrometry Mass spectroscopy Medical Education Pharmacodynamics Pharmacokinetics Pharmacology Potassium |
| title | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Escalating Single and Multiple Oral Doses of CJ-12420 (Tegoprazan), A Novel Potassium-Competitive Acid Blocker (P-CAB) in Healthy Male Subjects |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T05%3A18%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety,%20Tolerability,%20Pharmacokinetics,%20and%20Pharmacodynamics%20of%20Escalating%20Single%20and%20Multiple%20Oral%20Doses%20of%20CJ-12420%20(Tegoprazan),%20A%20Novel%20Potassium-Competitive%20Acid%20Blocker%20(P-CAB)%20in%20Healthy%20Male%20Subjects&rft.jtitle=Clinical%20therapeutics&rft.au=Han,%20S&rft.date=2017-08-01&rft.volume=39&rft.issue=8&rft.spage=e97&rft.epage=e98&rft.pages=e97-e98&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2017.05.306&rft_dat=%3Cproquest_cross%3E1912661634%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1912661634&rft_id=info:pmid/&rft_els_id=S0149291817306045&rfr_iscdi=true |